Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen
Summary An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adju...
Saved in:
Published in: | Vaccine Vol. 26; no. 22; pp. 2680 - 2688 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford
Elsevier Ltd
23-05-2008
Elsevier Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Summary An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFNγ production. Additionally, IL-12 was not required for PCEP induced IFNγ response. We conclude that the polyphosphazene–CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. |
---|---|
AbstractList | An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFNgamma production. Additionally, IL-12 was not required for PCEP induced IFNgamma response. We conclude that the polyphosphazene-CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFNγ production. Additionally, IL-12 was not required for PCEP induced IFNγ response. We conclude that the polyphosphazene-CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. Summary An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFNγ production. Additionally, IL-12 was not required for PCEP induced IFNγ response. We conclude that the polyphosphazene–CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFNg production. Additionally, IL-12 was not required for PCEP induced IFNg response. We conclude that the polyphosphazene-CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to vaccine antigens. We investigated whether the polyphosphazenes used in combination with CpG oligodeoxynucleotides (ODN) were potent adjuvant formulations. BALB/c mice were immunized subcutaneously with Hepatitis B surface antigen (HBsAg) alone, or in various combinations with poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP), poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) or CpG ODN. All three adjuvants enhanced HBsAg-specific IgG1 antibody responses with PCEP inducing the highest responses. PCEP and CpG ODN significantly enhanced the Th1-associated antibody isotype IgG2a. As expected CpG ODN induced predominantly Th1-type immune responses while PCEP was associated with mixed Th1/Th2 immune responses. Interestingly, PCEP and PCPP synergized with CpG ODN to further enhance antibody responses. Since the mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, we investigated whether PCEP and PCPP could stimulate innate immune responses. Incubation of mouse splenocytes with PCEP or PCPP (in the absence of antigen) stimulated production of IL-4 and IL-12, but only PCEP induced significant IFN gamma production. Additionally, IL-12 was not required for PCEP induced IFN gamma response. We conclude that the polyphosphazene-CpG ODN combination is a potent adjuvant formulation that is more effective in enhancing immune responses than either of the individual adjuvants. In addition, we provide evidence that PCEP and PCPP can stimulate innate cytokine production, suggesting a potential mechanism by which polyphosphazenes achieve their potent adjuvant effects. |
Author | Mutwiri, George Babiuk, Lorne A Soita, Henry Benjamin, Ponn |
Author_xml | – sequence: 1 fullname: Mutwiri, George – sequence: 2 fullname: Benjamin, Ponn – sequence: 3 fullname: Soita, Henry – sequence: 4 fullname: Babiuk, Lorne A |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20328867$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18430493$$D View this record in MEDLINE/PubMed |
BookMark | eNqFklGL1DAQx4OceHurH0EpiOJL10nSbLMvii56Jxz4oIJvIU2nu1nbpJe0q3ufxo9qyi4e3INCIJD5zX9m8p8Lcua8Q0KeUlhQoMvXu8VeG2MdLhiAXABPhz4gMypLnjNB5RmZAVsWeUHh-zm5iHEHAILT1SNyTmXBoVjxGfm99rmuO-tsHIIerHeZb7Let4d-62O_1bfoMGY_7bDN1v1l5lu78TX6Xwc3mhb9YOsUTrnebdpDhm6rnUkvtutGh1nA2HsXpweXddbgMWBvsT5qXmGfqg42Zu-zvQ1j0hpDoxOo3WA36B6Th41uIz453XPy7eOHr-ur_Prz5af1u-vciAKGXK4MVsUKGNeGL7XWQnMOEmVtZFUuURS0ZjXISlAQskGhTSUbVnPNaCmg4nPy8qjbB38zYhxUZ6PBttUO_RgVg1W5AsoS-OqfIBUApZS0kAl9fg_d-TG4NEaixMSUyYg5EUfKBB9jwEb1wXY6HBQFNXmtdurktZq8VsDToSnv2Ul9rDqs77JO5ibgxQnQ0ei2CckaG_9yDDiTclkm7u2Rw_S_e4tBRWMx2VjbgGZQtbf_beXNPQXTppVKRX_gAePd1CoyBerLtJjTXoIE4Dw18gc0e-Sq |
CODEN | VACCDE |
CitedBy_id | crossref_primary_10_1016_j_addr_2008_12_004 crossref_primary_10_1016_j_vaccine_2015_12_060 crossref_primary_10_1016_j_addr_2008_12_003 crossref_primary_10_1080_21645515_2021_1875763 crossref_primary_10_1016_j_addr_2008_12_009 crossref_primary_10_1016_j_vaccine_2016_12_023 crossref_primary_10_1128_CVI_00250_09 crossref_primary_10_1186_1476_8518_8_4 crossref_primary_10_1016_j_vaccine_2009_01_117 crossref_primary_10_1637_11202_052815_Reg_1 crossref_primary_10_1007_s00441_018_2929_4 crossref_primary_10_1038_emi_2012_17 crossref_primary_10_1016_j_hlife_2023_12_005 crossref_primary_10_1016_j_vaccine_2014_03_014 crossref_primary_10_1021_acs_molpharmaceut_0c00487 crossref_primary_10_1016_j_vetimm_2019_02_004 crossref_primary_10_1039_D3BM01970E crossref_primary_10_1586_erv_10_89 crossref_primary_10_1016_j_vaccine_2010_09_080 crossref_primary_10_1016_j_exppara_2012_05_002 crossref_primary_10_7774_cevr_2015_4_1_23 crossref_primary_10_1002_jat_1683 crossref_primary_10_1016_j_vetimm_2016_05_003 crossref_primary_10_1016_j_antiviral_2015_01_007 crossref_primary_10_1016_j_vaccine_2010_10_006 crossref_primary_10_1134_S1070363217050188 crossref_primary_10_1016_j_vetimm_2012_01_021 crossref_primary_10_3390_vaccines2030500 crossref_primary_10_1016_j_vaccine_2018_02_026 crossref_primary_10_1098_rsif_2012_0536 crossref_primary_10_3390_vaccines8020235 crossref_primary_10_1586_erv_10_154 crossref_primary_10_1021_acs_molpharmaceut_2c00489 crossref_primary_10_1016_j_vaccine_2011_09_062 crossref_primary_10_1016_j_jiec_2019_04_044 crossref_primary_10_3390_vaccines10060927 crossref_primary_10_1016_j_vaccine_2009_12_069 crossref_primary_10_1016_j_molimm_2012_03_026 crossref_primary_10_1016_j_ejpb_2010_12_017 crossref_primary_10_1016_j_vaccine_2013_06_058 crossref_primary_10_1016_j_vaccine_2009_02_016 crossref_primary_10_3389_fbioe_2021_625482 crossref_primary_10_4155_tde_10_19 crossref_primary_10_1016_j_cca_2011_01_006 crossref_primary_10_1016_j_nano_2017_05_012 crossref_primary_10_1016_j_ijpharm_2019_118731 crossref_primary_10_1016_j_jconrel_2020_12_001 crossref_primary_10_3389_fimmu_2017_00037 crossref_primary_10_3390_vaccines9050507 |
Cites_doi | 10.1006/clin.1997.4380 10.1016/j.vaccine.2007.11.054 10.4049/jimmunol.160.2.870 10.4049/jimmunol.136.12.4538 10.1016/j.vaccine.2006.10.011 10.1016/j.vaccine.2003.09.030 10.1016/S0264-410X(03)00003-3 10.1016/S0264-410X(98)00157-1 10.1006/cimm.1996.0009 10.1016/S0264-410X(98)00359-4 10.1093/intimm/5.8.885 10.4049/jimmunol.162.9.5536 10.1016/j.vaccine.2005.06.024 10.1016/S0264-410X(97)00149-7 10.1016/S0264-410X(02)00169-X 10.1093/intimm/dxg049 10.1126/science.272.5258.50 10.1021/bm049329t 10.1097/01.aids.0000183514.37513.d2 10.1126/science.3107127 10.1128/IAI.69.12.7695-7702.2001 10.4049/jimmunol.162.7.3942 10.1016/S0264-410X(02)00378-X 10.1146/annurev.iy.08.040190.001511 10.1128/JVI.76.18.9002-9010.2002 10.1016/S1389-0344(01)00101-0 10.1073/pnas.93.7.2879 10.1146/annurev.immunol.15.1.297 10.1146/annurev.immunol.21.120601.140942 10.1016/S0169-409X(01)00170-3 10.1038/nri1001 |
ContentType | Journal Article |
Copyright | Elsevier Ltd 2008 Elsevier Ltd 2008 INIST-CNRS Copyright Elsevier Limited May 23, 2008 |
Copyright_xml | – notice: Elsevier Ltd – notice: 2008 Elsevier Ltd – notice: 2008 INIST-CNRS – notice: Copyright Elsevier Limited May 23, 2008 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI Q9U |
DOI | 10.1016/j.vaccine.2008.03.031 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | MEDLINE Research Library Prep AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 2688 |
ExternalDocumentID | 3419607261 10_1016_j_vaccine_2008_03_031 18430493 20328867 S0264410X08003320 1_s2_0_S0264410X08003320 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 0SF 123 1B1 1P~ 1RT 1~. 1~5 29Q 3V. 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABXDB ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AEXOQ AFCTW AFJKZ AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 R2- RIG ROL RPZ SAB SAE SCC SDF SDG SDP SES SEW SIN SNL SPCBC SSH SSI SSZ SVS T5K UV1 WH7 WOW WUQ XPP Z5R ZGI ZXP ~G- AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG HMCUK LCYCR QYZTP UKHRP ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PQEST PQUKI Q9U |
ID | FETCH-LOGICAL-c540t-89ceb49023ac36aaa5a3308e8dc8b76e541d2d08b51058fe5acb8f2d3a21750b3 |
ISSN | 0264-410X |
IngestDate | Fri Oct 25 23:10:56 EDT 2024 Thu Oct 24 23:50:39 EDT 2024 Fri Nov 08 08:08:47 EST 2024 Thu Sep 26 18:01:58 EDT 2024 Sat Sep 28 07:54:45 EDT 2024 Sun Oct 22 16:06:05 EDT 2023 Fri Feb 23 02:32:31 EST 2024 Tue Oct 15 22:55:52 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Polyphosphazenes PCPP Adjuvants HBsAg PCEP CpG ODN Vaccines Immunization Hepatitis B surface antigen Immune response Rodentia Orthohepadnavirus Vaccine Virus Vertebrata Mammalia Mouse Hepadnaviridae Immunological adjuvant Hepatitis B virus |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c540t-89ceb49023ac36aaa5a3308e8dc8b76e541d2d08b51058fe5acb8f2d3a21750b3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 18430493 |
PQID | 1558814784 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_20979012 proquest_miscellaneous_1500788148 proquest_journals_1558814784 crossref_primary_10_1016_j_vaccine_2008_03_031 pubmed_primary_18430493 pascalfrancis_primary_20328867 elsevier_sciencedirect_doi_10_1016_j_vaccine_2008_03_031 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X08003320 |
PublicationCentury | 2000 |
PublicationDate | 2008-05-23 |
PublicationDateYYYYMMDD | 2008-05-23 |
PublicationDate_xml | – month: 05 year: 2008 text: 2008-05-23 day: 23 |
PublicationDecade | 2000 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2008 |
Publisher | Elsevier Ltd Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
References | Arulanandam, Metzger (bib29) 1999; 17 Boyaka, McGhee (bib24) 2001; 51 Coffman, Ohara, Bond, Carty, Zlotnik, Paul (bib32) 1986; 136 Collins, Dunnick (bib31) 1993; 5 McNeal, Rae, Ward (bib13) 1999; 17 Cribbs, Ghochikyan, Vasilevko, Tran, Petrushina, Sadzikava (bib19) 2003; 15 Wack, Baudner, Hilbert, Manini, Nuti, Tavarini (bib11) 2008; 26 Chace, Hooker, Mildenstein, Krieg, Cowdery (bib34) 1997; 84 Snapper, Paul (bib30) 1987; 236 Weeratna, Makinen, McCluskie, Davis (bib27) 2005; 23 Halpern, Kurlander, Pisetsky (bib33) 1996; 167 Klinman, Yi, Beaucage, Conover, Krieg (bib4) 1996; 93 HogenEsch (bib10) 2002; 20 Constant, Bottomly (bib18) 1997; 15 Mazumdar, Anam, Ali (bib20) 2004; 22 Trinchieri (bib28) 2003; 3 Smith, Donachie, Grdic, Lycke, Mowat (bib26) 1999; 162 Ramon (bib1) 1924; 38 Mutwiri, Benjamin, Soita, Townsend, Yost, Roberts (bib15) 2007; 25 Yip, Karulin, Tary-Lehmann, Hesse, Radeke, Heeger (bib21) 1999; 162 Fearon, Locksley (bib3) 1996; 272 Szabo, Sullivan, Peng, Glimcher (bib23) 2003; 21 Cooper, Davis, Angel, Morris, Elfer, Seguin (bib5) 2005; 19 Alcon, Foldvari, Snider, Willson, Gomis, Hecker (bib6) 2003; 21 Andrianov, Marin, Roberts (bib16) 2005; 6 Payne, Jenkins, Woods, Grund, Geribo, Loebelenz (bib12) 1998; 16 Finkelman, Holmes, Katona, Urban, Beckmann, Park (bib22) 1990; 8 Heath (bib25) 1995 Wu, Wade, Taylor (bib14) 2001; 69 Davis, Weeratna, Waldschmidt, Tygrett, Schorr, Krieg (bib7) 1998; 160 Ioannou, Griebel, Hecker, Babiuk, van Drunen Littel-van den Hurk (bib8) 2002; 76 Andrianov, Svirkin, LeGolvan (bib17) 2004; 5 O’Hagan, MacKichan, Singh (bib2) 2001; 18 Ioannou, Gomis, Karvonen, Hecker, Babiuk, van Drunen Littel-van den Hurk (bib9) 2002; 21 Payne (10.1016/j.vaccine.2008.03.031_bib12) 1998; 16 Cribbs (10.1016/j.vaccine.2008.03.031_bib19) 2003; 15 Heath (10.1016/j.vaccine.2008.03.031_bib25) 1995 McNeal (10.1016/j.vaccine.2008.03.031_bib13) 1999; 17 Szabo (10.1016/j.vaccine.2008.03.031_bib23) 2003; 21 Coffman (10.1016/j.vaccine.2008.03.031_bib32) 1986; 136 Boyaka (10.1016/j.vaccine.2008.03.031_bib24) 2001; 51 Collins (10.1016/j.vaccine.2008.03.031_bib31) 1993; 5 Finkelman (10.1016/j.vaccine.2008.03.031_bib22) 1990; 8 Smith (10.1016/j.vaccine.2008.03.031_bib26) 1999; 162 Trinchieri (10.1016/j.vaccine.2008.03.031_bib28) 2003; 3 Chace (10.1016/j.vaccine.2008.03.031_bib34) 1997; 84 Davis (10.1016/j.vaccine.2008.03.031_bib7) 1998; 160 Constant (10.1016/j.vaccine.2008.03.031_bib18) 1997; 15 Ramon (10.1016/j.vaccine.2008.03.031_bib1) 1924; 38 O’Hagan (10.1016/j.vaccine.2008.03.031_bib2) 2001; 18 Wack (10.1016/j.vaccine.2008.03.031_bib11) 2008; 26 Wu (10.1016/j.vaccine.2008.03.031_bib14) 2001; 69 Arulanandam (10.1016/j.vaccine.2008.03.031_bib29) 1999; 17 Yip (10.1016/j.vaccine.2008.03.031_bib21) 1999; 162 Ioannou (10.1016/j.vaccine.2008.03.031_bib9) 2002; 21 HogenEsch (10.1016/j.vaccine.2008.03.031_bib10) 2002; 20 Ioannou (10.1016/j.vaccine.2008.03.031_bib8) 2002; 76 Mutwiri (10.1016/j.vaccine.2008.03.031_bib15) 2007; 25 Klinman (10.1016/j.vaccine.2008.03.031_bib4) 1996; 93 Cooper (10.1016/j.vaccine.2008.03.031_bib5) 2005; 19 Mazumdar (10.1016/j.vaccine.2008.03.031_bib20) 2004; 22 Snapper (10.1016/j.vaccine.2008.03.031_bib30) 1987; 236 Fearon (10.1016/j.vaccine.2008.03.031_bib3) 1996; 272 Andrianov (10.1016/j.vaccine.2008.03.031_bib17) 2004; 5 Alcon (10.1016/j.vaccine.2008.03.031_bib6) 2003; 21 Andrianov (10.1016/j.vaccine.2008.03.031_bib16) 2005; 6 Halpern (10.1016/j.vaccine.2008.03.031_bib33) 1996; 167 Weeratna (10.1016/j.vaccine.2008.03.031_bib27) 2005; 23 |
References_xml | – volume: 38 start-page: 1 year: 1924 ident: bib1 publication-title: Ann Inst Pasteur contributor: fullname: Ramon – volume: 25 start-page: 1204 year: 2007 end-page: 1213 ident: bib15 article-title: Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens publication-title: Vaccine contributor: fullname: Roberts – volume: 5 start-page: 885 year: 1993 end-page: 891 ident: bib31 article-title: Germline transcripts of the murine immunoglobulin gamma 2a gene: structure and induction by IFN-gamma publication-title: Int Immunol contributor: fullname: Dunnick – volume: 76 start-page: 9002 year: 2002 end-page: 9010 ident: bib8 article-title: The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides publication-title: J Virol contributor: fullname: van Drunen Littel-van den Hurk – volume: 162 start-page: 3942 year: 1999 end-page: 3949 ident: bib21 article-title: Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response publication-title: J Immunol contributor: fullname: Heeger – volume: 160 start-page: 870 year: 1998 end-page: 876 ident: bib7 article-title: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen publication-title: J Immunol contributor: fullname: Krieg – volume: 167 start-page: 72 year: 1996 end-page: 78 ident: bib33 article-title: Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha publication-title: Cell Immunol contributor: fullname: Pisetsky – volume: 21 start-page: 713 year: 2003 end-page: 758 ident: bib23 article-title: Molecular mechanisms regulating Th1 immune responses publication-title: Annu Rev Immunol contributor: fullname: Glimcher – volume: 162 start-page: 5536 year: 1999 end-page: 5546 ident: bib26 article-title: Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses publication-title: J Immunol contributor: fullname: Mowat – volume: 51 start-page: 71 year: 2001 end-page: 79 ident: bib24 article-title: Cytokines as adjuvants for the induction of mucosal immunity publication-title: Adv Drug Deliv Rev contributor: fullname: McGhee – volume: 236 start-page: 944 year: 1987 end-page: 947 ident: bib30 article-title: Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production publication-title: Science contributor: fullname: Paul – volume: 84 start-page: 185 year: 1997 end-page: 193 ident: bib34 article-title: Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 publication-title: Clin Immunol Immunopathol contributor: fullname: Cowdery – year: 1995 ident: bib25 article-title: Cytokines as immunological adjuvants contributor: fullname: Heath – volume: 26 start-page: 552 year: 2008 end-page: 561 ident: bib11 article-title: Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice publication-title: Vaccine contributor: fullname: Tavarini – volume: 23 start-page: 5263 year: 2005 end-page: 5270 ident: bib27 article-title: TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848) publication-title: Vaccine contributor: fullname: Davis – volume: 20 start-page: S34 year: 2002 end-page: S39 ident: bib10 article-title: Mechanisms of stimulation of the immune response by aluminum adjuvants publication-title: Vaccine contributor: fullname: HogenEsch – volume: 22 start-page: 1162 year: 2004 end-page: 1171 ident: bib20 article-title: A mixed Th1/Th2 response elicited by a liposomal formulation of publication-title: Vaccine contributor: fullname: Ali – volume: 69 start-page: 7695 year: 2001 end-page: 7702 ident: bib14 article-title: Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice publication-title: Infect Immun contributor: fullname: Taylor – volume: 6 start-page: 1375 year: 2005 end-page: 1379 ident: bib16 article-title: Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity publication-title: Biomacromolecules contributor: fullname: Roberts – volume: 21 start-page: 127 year: 2002 end-page: 137 ident: bib9 article-title: CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein publication-title: Vaccine contributor: fullname: van Drunen Littel-van den Hurk – volume: 17 start-page: 1573 year: 1999 end-page: 1580 ident: bib13 article-title: Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus publication-title: Vaccine contributor: fullname: Ward – volume: 136 start-page: 4538 year: 1986 end-page: 4541 ident: bib32 article-title: B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells publication-title: J Immunol contributor: fullname: Paul – volume: 93 start-page: 2879 year: 1996 end-page: 2883 ident: bib4 article-title: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma publication-title: Proc Natl Acad Sci USA contributor: fullname: Krieg – volume: 18 start-page: 69 year: 2001 end-page: 85 ident: bib2 article-title: Recent developments in adjuvants for vaccines against infectious diseases publication-title: Biomol Eng contributor: fullname: Singh – volume: 21 start-page: 1811 year: 2003 end-page: 1814 ident: bib6 article-title: Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix) publication-title: Vaccine contributor: fullname: Hecker – volume: 15 start-page: 505 year: 2003 end-page: 514 ident: bib19 article-title: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid publication-title: Int Immunol contributor: fullname: Sadzikava – volume: 272 start-page: 50 year: 1996 end-page: 53 ident: bib3 article-title: The instructive role of innate immunity in the acquired immune response publication-title: Science contributor: fullname: Locksley – volume: 17 start-page: 252 year: 1999 end-page: 260 ident: bib29 article-title: Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery publication-title: Vaccine contributor: fullname: Metzger – volume: 16 start-page: 92 year: 1998 end-page: 98 ident: bib12 article-title: Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine publication-title: Vaccine contributor: fullname: Loebelenz – volume: 5 start-page: 1999 year: 2004 end-page: 2006 ident: bib17 article-title: Synthesis and biologically relevant properties of polyphosphazene polyacids publication-title: Biomolecules contributor: fullname: LeGolvan – volume: 19 start-page: 1473 year: 2005 end-page: 1479 ident: bib5 article-title: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults publication-title: AIDS contributor: fullname: Seguin – volume: 3 start-page: 133 year: 2003 end-page: 146 ident: bib28 article-title: Interleukin-12 and the regulation of innate resistance and adaptive immunity publication-title: Nat Rev Immunol contributor: fullname: Trinchieri – volume: 15 start-page: 297 year: 1997 end-page: 322 ident: bib18 article-title: Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches publication-title: Annu Rev Immunol contributor: fullname: Bottomly – volume: 8 start-page: 303 year: 1990 end-page: 333 ident: bib22 article-title: Lymphokine control of in vivo immunoglobulin isotype selection publication-title: Annu Rev Immunol contributor: fullname: Park – volume: 84 start-page: 185 issue: 2 year: 1997 ident: 10.1016/j.vaccine.2008.03.031_bib34 article-title: Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 publication-title: Clin Immunol Immunopathol doi: 10.1006/clin.1997.4380 contributor: fullname: Chace – volume: 26 start-page: 552 issue: 4 year: 2008 ident: 10.1016/j.vaccine.2008.03.031_bib11 article-title: Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice publication-title: Vaccine doi: 10.1016/j.vaccine.2007.11.054 contributor: fullname: Wack – year: 1995 ident: 10.1016/j.vaccine.2008.03.031_bib25 contributor: fullname: Heath – volume: 38 start-page: 1 year: 1924 ident: 10.1016/j.vaccine.2008.03.031_bib1 publication-title: Ann Inst Pasteur contributor: fullname: Ramon – volume: 160 start-page: 870 issue: 2 year: 1998 ident: 10.1016/j.vaccine.2008.03.031_bib7 article-title: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen publication-title: J Immunol doi: 10.4049/jimmunol.160.2.870 contributor: fullname: Davis – volume: 136 start-page: 4538 issue: 12 year: 1986 ident: 10.1016/j.vaccine.2008.03.031_bib32 article-title: B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells publication-title: J Immunol doi: 10.4049/jimmunol.136.12.4538 contributor: fullname: Coffman – volume: 25 start-page: 1204 issue: 7 year: 2007 ident: 10.1016/j.vaccine.2008.03.031_bib15 article-title: Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens publication-title: Vaccine doi: 10.1016/j.vaccine.2006.10.011 contributor: fullname: Mutwiri – volume: 22 start-page: 1162 issue: 9–10 year: 2004 ident: 10.1016/j.vaccine.2008.03.031_bib20 article-title: A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice publication-title: Vaccine doi: 10.1016/j.vaccine.2003.09.030 contributor: fullname: Mazumdar – volume: 21 start-page: 1811 issue: 17–18 year: 2003 ident: 10.1016/j.vaccine.2008.03.031_bib6 article-title: Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix) publication-title: Vaccine doi: 10.1016/S0264-410X(03)00003-3 contributor: fullname: Alcon – volume: 17 start-page: 252 issue: 3 year: 1999 ident: 10.1016/j.vaccine.2008.03.031_bib29 article-title: Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery publication-title: Vaccine doi: 10.1016/S0264-410X(98)00157-1 contributor: fullname: Arulanandam – volume: 167 start-page: 72 issue: 1 year: 1996 ident: 10.1016/j.vaccine.2008.03.031_bib33 article-title: Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha publication-title: Cell Immunol doi: 10.1006/cimm.1996.0009 contributor: fullname: Halpern – volume: 17 start-page: 1573 issue: 11–12 year: 1999 ident: 10.1016/j.vaccine.2008.03.031_bib13 article-title: Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus publication-title: Vaccine doi: 10.1016/S0264-410X(98)00359-4 contributor: fullname: McNeal – volume: 5 start-page: 885 issue: 8 year: 1993 ident: 10.1016/j.vaccine.2008.03.031_bib31 article-title: Germline transcripts of the murine immunoglobulin gamma 2a gene: structure and induction by IFN-gamma publication-title: Int Immunol doi: 10.1093/intimm/5.8.885 contributor: fullname: Collins – volume: 162 start-page: 5536 issue: 9 year: 1999 ident: 10.1016/j.vaccine.2008.03.031_bib26 article-title: Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses publication-title: J Immunol doi: 10.4049/jimmunol.162.9.5536 contributor: fullname: Smith – volume: 23 start-page: 5263 issue: 45 year: 2005 ident: 10.1016/j.vaccine.2008.03.031_bib27 article-title: TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848) publication-title: Vaccine doi: 10.1016/j.vaccine.2005.06.024 contributor: fullname: Weeratna – volume: 16 start-page: 92 issue: 1 year: 1998 ident: 10.1016/j.vaccine.2008.03.031_bib12 article-title: Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine publication-title: Vaccine doi: 10.1016/S0264-410X(97)00149-7 contributor: fullname: Payne – volume: 20 start-page: S34 issue: Suppl. 3 year: 2002 ident: 10.1016/j.vaccine.2008.03.031_bib10 article-title: Mechanisms of stimulation of the immune response by aluminum adjuvants publication-title: Vaccine doi: 10.1016/S0264-410X(02)00169-X contributor: fullname: HogenEsch – volume: 15 start-page: 505 issue: 4 year: 2003 ident: 10.1016/j.vaccine.2008.03.031_bib19 article-title: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid publication-title: Int Immunol doi: 10.1093/intimm/dxg049 contributor: fullname: Cribbs – volume: 272 start-page: 50 issue: 5258 year: 1996 ident: 10.1016/j.vaccine.2008.03.031_bib3 article-title: The instructive role of innate immunity in the acquired immune response publication-title: Science doi: 10.1126/science.272.5258.50 contributor: fullname: Fearon – volume: 6 start-page: 1375 issue: 3 year: 2005 ident: 10.1016/j.vaccine.2008.03.031_bib16 article-title: Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity publication-title: Biomacromolecules doi: 10.1021/bm049329t contributor: fullname: Andrianov – volume: 19 start-page: 1473 issue: 14 year: 2005 ident: 10.1016/j.vaccine.2008.03.031_bib5 article-title: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults publication-title: AIDS doi: 10.1097/01.aids.0000183514.37513.d2 contributor: fullname: Cooper – volume: 236 start-page: 944 issue: 4804 year: 1987 ident: 10.1016/j.vaccine.2008.03.031_bib30 article-title: Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production publication-title: Science doi: 10.1126/science.3107127 contributor: fullname: Snapper – volume: 69 start-page: 7695 issue: 12 year: 2001 ident: 10.1016/j.vaccine.2008.03.031_bib14 article-title: Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice publication-title: Infect Immun doi: 10.1128/IAI.69.12.7695-7702.2001 contributor: fullname: Wu – volume: 162 start-page: 3942 issue: 7 year: 1999 ident: 10.1016/j.vaccine.2008.03.031_bib21 article-title: Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response publication-title: J Immunol doi: 10.4049/jimmunol.162.7.3942 contributor: fullname: Yip – volume: 21 start-page: 127 issue: 1–2 year: 2002 ident: 10.1016/j.vaccine.2008.03.031_bib9 article-title: CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein publication-title: Vaccine doi: 10.1016/S0264-410X(02)00378-X contributor: fullname: Ioannou – volume: 8 start-page: 303 year: 1990 ident: 10.1016/j.vaccine.2008.03.031_bib22 article-title: Lymphokine control of in vivo immunoglobulin isotype selection publication-title: Annu Rev Immunol doi: 10.1146/annurev.iy.08.040190.001511 contributor: fullname: Finkelman – volume: 76 start-page: 9002 issue: 18 year: 2002 ident: 10.1016/j.vaccine.2008.03.031_bib8 article-title: The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides publication-title: J Virol doi: 10.1128/JVI.76.18.9002-9010.2002 contributor: fullname: Ioannou – volume: 18 start-page: 69 issue: 3 year: 2001 ident: 10.1016/j.vaccine.2008.03.031_bib2 article-title: Recent developments in adjuvants for vaccines against infectious diseases publication-title: Biomol Eng doi: 10.1016/S1389-0344(01)00101-0 contributor: fullname: O’Hagan – volume: 93 start-page: 2879 issue: 7 year: 1996 ident: 10.1016/j.vaccine.2008.03.031_bib4 article-title: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.7.2879 contributor: fullname: Klinman – volume: 15 start-page: 297 year: 1997 ident: 10.1016/j.vaccine.2008.03.031_bib18 article-title: Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.297 contributor: fullname: Constant – volume: 21 start-page: 713 year: 2003 ident: 10.1016/j.vaccine.2008.03.031_bib23 article-title: Molecular mechanisms regulating Th1 immune responses publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.21.120601.140942 contributor: fullname: Szabo – volume: 5 start-page: 1999 year: 2004 ident: 10.1016/j.vaccine.2008.03.031_bib17 article-title: Synthesis and biologically relevant properties of polyphosphazene polyacids publication-title: Biomolecules contributor: fullname: Andrianov – volume: 51 start-page: 71 issue: 1–3 year: 2001 ident: 10.1016/j.vaccine.2008.03.031_bib24 article-title: Cytokines as adjuvants for the induction of mucosal immunity publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(01)00170-3 contributor: fullname: Boyaka – volume: 3 start-page: 133 issue: 2 year: 2003 ident: 10.1016/j.vaccine.2008.03.031_bib28 article-title: Interleukin-12 and the regulation of innate resistance and adaptive immunity publication-title: Nat Rev Immunol doi: 10.1038/nri1001 contributor: fullname: Trinchieri |
SSID | ssj0005319 |
Score | 2.1816041 |
Snippet | Summary An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune... An emerging paradigm in vaccinology is that multiple adjuvant combinations may be more effective than individual adjuvants in enhancing immune responses to... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2680 |
SubjectTerms | Adjuvants Adjuvants, Immunologic - administration & dosage Allergy and Immunology Animals Applied microbiology Biological and medical sciences Cells, Cultured CpG ODN Drug Synergism Fundamental and applied biological sciences. Psychology HBsAg Hepatitis Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - immunology Hepatitis B virus Immune system Immunization Immunoglobulin G - blood Injections, Subcutaneous Interferon-gamma - biosynthesis Interleukin-12 - biosynthesis Interleukin-2 - biosynthesis Laboratories Leukocytes, Mononuclear - immunology Medical research Mice Mice, Inbred BALB C Microbiology Miscellaneous Oligodeoxyribonucleotides - administration & dosage Oligodeoxyribonucleotides - immunology Organophosphorus Compounds - administration & dosage Organophosphorus Compounds - immunology PCEP PCPP Polymers - administration & dosage Polyphosphazenes Rodents Sodium Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology |
Title | Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X08003320 https://dx.doi.org/10.1016/j.vaccine.2008.03.031 https://www.ncbi.nlm.nih.gov/pubmed/18430493 https://www.proquest.com/docview/1558814784 https://search.proquest.com/docview/1500788148 https://search.proquest.com/docview/20979012 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tT9RAEN4ARmNijJ6ip4hrYvhy9Nzubq97HwFRvmCIICF-abbtVkqwvVyv6PFr_KnOdPsCAvElMWmau76383R2ZvrMDCGvJQ9DHMccMTbKkTqJnbF2Q0dFETcyjBPNMd95Z9__cKTebsvthYWmcUG37L9KGpaBrDFz9i-k3R4UFsBvkDnMQeow_yO5b-WOvlQQt-I056fzyXFeTI71OSo3G37dmrwf5KcpeKYm_z7PsLJxPktjWF1ggPzL6XxgsmOERTFIMY8EW6xUlNqKxTXATvZ2RXresNh3DFK0Z2kx2BycpdMSjlVOE12lJcyw8udFa_hQRxe_6--Ws2-pzXy3ofo2VmCyE_3VVjvYy7MWz_t5ao3fKtWiC8qGaWnbw-dTuOaN4aXQhsKv8jb72MbbmpybjuBUVKVipSNddmRHMKu2lS8csNTURb1uM_Fr_Nrk50ZLj2z3qHrEh7_q2tHEBjZOhmf2adTMWwGT2w2fLalxn1XGJTtCI1wIzhbJLQ7qD4mmn72PHfFIVO1m2vvo8sreXHuqmyymexNdwHuc2AYsN3tIlaV08IDcr10cumGx-ZAsmKxHbtump_MeubNb0zl6ZG3PFk6fr9ODLg-wWKdrdK8rqQ779A6RtVWljtNm90fkxxWs0zyhv2KdIi4pYJ1ei3XaYJ02WKcW67TFOk0zilinLdbtMVus001aYZ3WWKc11h-TT--2D7Z2nLrjiBOB5zJz1DgyoRyDHasjMdJae1oIpoyKIxX6I-NJN-YxUyG6JSoxno5ClfBYaPDsPRaKZbKU5Zl5SqhnsJIji5lIYulKNeYsDjUovxFnPBKqT4aNVIOJLSwTNIzLk6CGQd0kVsDk9onfyD5osqZhnDdFrXyKwA0KHrDgCg77RLV71na1tZcDAPrvTrp6CWXtpXKsw6lGfp-sNLALugvxPKVc6SvZJ6_a1TBu4cdInZm8xG3QO4Gt4Em8vGEbzsY--Cu8T55YQHdPSknkB4hn_35rz8ndTueskKXZtDQvyGIRl6vV-_oTDz0xJw |
link.rule.ids | 315,782,786,27935,27936 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-administration+of+polyphosphazenes+with+CpG+oligodeoxynucleotides+strongly+enhances+immune+responses+in+mice+immunized+with+Hepatitis+B+virus+surface+antigen&rft.jtitle=Vaccine&rft.au=Mutwiri%2C+George&rft.au=Benjamin%2C+Ponn&rft.au=Soita%2C+Henry&rft.au=Babiuk%2C+Lorne+A.&rft.date=2008-05-23&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=26&rft.issue=22&rft.spage=2680&rft.epage=2688&rft_id=info:doi/10.1016%2Fj.vaccine.2008.03.031&rft.externalDocID=S0264410X08003320 |
thumbnail_m | http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X08X00210%2Fcov150h.gif |